Ar­cus and As­traZeneca part­ner on a high stakes an­ti-TIG­IT/PD-L1 PhI­II can­cer study, look­ing to im­prove on a stan­dard of care

For As­traZeneca, the PA­CIF­IC tri­al in Stage III non-small cell lung can­cer re­mains one of the big tri­umphs for As­traZeneca’s on­col­o­gy R&D group. It not …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.